http://www.nationalmssociety.org/articles.asp?SMContentIndex=0&SMContentSet=0
FaxWatch Inc.- June 21, 2001
In a recent study, researchers sought
to assess the practice effects, reliability and validity of the Multiple
Sclerosis Functional Composite (MSFC) measure—a test that measures leg,
arm and cognitive function.
The study included 436 patients who
were participants of the International Multiple Sclerosis Secondary Progressive
Avonex Controlled trial. These patients underwent three baseline MSFC testing
sessions prior to randomization.
The study “confirmed the excellent
reliability of the MSFC when standardized procedures are used to train
examiners and to assess patients,” the authors wrote.
The investigators noted that compared
with the Kurtzke Expanded Disability Status Scale (EDSS),which is used
by physicians to follow the progression of MS disability and to evaluate
treatment results for similar groupings of patients,“the MSFC [assessed]
aspects of neurologic function not measured by the EDSS.”
Therefore, the MSFC “will be more
sensitive to detect change over time and better able to demonstrate a therapeutic
effect when one exists,” they concluded.
The study appears in the June issue
of Archives of Neurology.
To see more of The Faxwatch Inc.,
or to subscribe, go to http://www.faxwatch.com
Copyright 2000 FaxWatch Inc. All
Rights Reserved.